FARAPULSE Pulsed Field Ablation System (FARAWAVE Pulsed Field Ablation Catheter, FARASTAR Catheter Connection Cable,
Farapulse, Inc. · Decision date Jan 30, 2024
What did the FDA approve?
The FDA approved the FARAPULSE Pulsed Field Ablation System on January 30, 2024. The approval covers the FARAWAVE Pulsed Field Ablation Catheter, FARASTAR Pulsed Field Ablation Generator, FARASTAR Recording System Module, FARASTAR Catheter Connection Cable, and associated cables. The catheter and generator are indicated for isolation of pulmonary veins in treating drug-refractory, recurrent, symptomatic paroxysmal atrial fibrillation.
The recording system module is indicated for use in an electrophysiology lab as a filtering/protection unit between the patient and attached recording or ECG systems, and as an interface for cardiac stimulation output. The connection cable is intended for use with a FARAPULSE catheter during an electrophysiology procedure for cardiac tissue ablation. The source statement reports intended use and indications; it does not independently establish safety or clinical effectiveness.
FDA approval order statement
approval for the FARAPULSE Pulsed Field Ablation System (FARAWAVE Pulsed Field Ablation Catheter, FARASTAR Catheter Connection Cable, FARASTAR Pulsed Field Ablation Generator, FARASTAR Recording System Module, FARASTAR Stimulation Module Cable, FARASTAR EGM Cable, FARASTAR Stimulation Module Male Cable, FARASTAR Stimulation Module Female Cable, FARASTAR Stimulation Module Female Cable, FARASTAR Stimulation Module Y-Cable Long, FARASTAR Stimulation Module Y-Cable Short, FARASTAR Recording System Module Catheter Pin Cable, FARASTAR Recording System Module ECG Trunk Cable (AAMI/IEC), FARASTAR Recording System Module ECG Output Cable (AAMI/IEC), FARASTAR Recording System Module EGM Input Module, FARASTAR SNAP CABLE R/L (AAMI/IEC), FARASTAR SNAP CABLE V SET (AAMI/IEC)). This device is indicated for:FARAWAVE Pulsed Field Ablation Catheter: The FARAWAVE Catheter is indicated for the isolation of pulmonary veins in the treatment of drug-refractory, recurrent, symptomatic Paroxysmal Atrial Fibrillation (PAF).FARASTAR Pulsed Field Ablation Generator: The FARASTAR PFA Generator when used in conjunction with the FARAWAVE PFA Catheter, is indicated for the isolation of pulmonary veins in the treatment of drug-refractory, recurrent, symptomatic Paroxysmal Atrial Fibrillation (PAF).FARASTAR Recording System Module: The FARASTAR Recording System Module (RSM) is indicated for use in an electrophysiology lab environment, as a filtering/protection unit to be connected between the patient and any attached recording systems and/or ECG systems, and as an interface for cardiac stimulation output. FARASTAR Catheter Connection Cable: The FARASTAR Connection Cable is intended to be used with a FARAPULSE Catheter during an Electrophysiology procedure for cardiac tissue ablation
- Regulatory pathway
- Original PMA
- Clinical specialty
- Cardiovascular
- Decision date
- Jan 30, 2024
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P230030
- Regulatory pathway
- Premarket approval application
- Applicant
- Farapulse, Inc.
- Product code
- QZI
- Decision code
- APPR
- Decision date
- Jan 30, 2024
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Percutaneous Cardiac Ablation Catheter for Treatment of Atrial Fibrillation with Irreversible Electroporation.
- Applicant
- Farapulse, Inc.
- Product code
- QZI
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P230030 received
Application receipt date recorded by FDA.
P230030 · FDA decision
APPR
P230030/S024 · Related supplement
FARASTAR Pulsed Field Ablation (PFA) Generator; FARASTAR Mapping System Module (MSM); FARASTAR Recording System Modul
P230030/S025 · Related supplement
FARAPULSE Pulsed Field Ablation System (FARAWAVE Pulsed Field Ablation Catheter, FARASTAR Catheter Connection Cable,
Timeline entries are records held by MedtechLedger for P230030. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P230030
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Farapulse, Inc. | PMA supplement | Sep 4, 2026 | FDA | |
| Farapulse, Inc. | PMA supplement | Oct 2, 2026 | FDA |
Explore the linked device profile
Other records with product code QZI
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Varipulse Bi-Directional CatheterP240006/S018 | Biosense Webster, Inc. | PMA supplement | Nov 3, 2026 | FDA |
Globe Catheter and Globe Pulsed Field SystemP240044/S007 | Kardium, Inc. | PMA supplement | Oct 27, 2026 | FDA |
Globe Pulsed Field System; Globe CatheterP240044/S008 | Kardium, Inc. | PMA supplement | Oct 23, 2026 | FDA |
Volt PFA SystemP250022/S002 | ABBOTT MEDICAL | PMA supplement | Oct 15, 2026 | FDA |
Affera Sphere-9 Mapping and Ablation CatheterP240013/S032 | Medtronic, Inc. | PMA supplement | Oct 9, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Farapulse, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 3715 Haven Ave., Suite 110, Menlo Park, CA, 94025
Sources and methodology
- Original FDA record: P230030
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

